291 related articles for article (PubMed ID: 20461087)
1. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
[TBL] [Abstract][Full Text] [Related]
2. Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy.
Fareed KR; Soomro IN; Hameed K; Arora A; Lobo DN; Parsons SL; Madhusudan S
World J Gastroenterol; 2012 Apr; 18(16):1915-20. PubMed ID: 22563171
[TBL] [Abstract][Full Text] [Related]
3. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
[TBL] [Abstract][Full Text] [Related]
4. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
[TBL] [Abstract][Full Text] [Related]
5. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma.
Woolston CM; Madhusudan S; Soomro IN; Lobo DN; Reece-Smith AM; Parsons SL; Martin SG
Redox Biol; 2013; 1(1):285-91. PubMed ID: 24024162
[TBL] [Abstract][Full Text] [Related]
7. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers.
Al-Attar A; Gossage L; Fareed KR; Shehata M; Mohammed M; Zaitoun AM; Soomro I; Lobo DN; Abbotts R; Chan S; Madhusudan S
Br J Cancer; 2010 Feb; 102(4):704-9. PubMed ID: 20087352
[TBL] [Abstract][Full Text] [Related]
8. Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction.
Li S; Li B; Wang J; Zhang D; Liu Z; Zhang Z; Zhang W; Wang Y; Bai D; Guan J; Zhang Y
Oncol Res; 2017 Jan; 25(1):93-97. PubMed ID: 28081737
[TBL] [Abstract][Full Text] [Related]
9. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
Langer R; Ott K; Feith M; Lordick F; Specht K; Becker K; Hofler H
J Surg Oncol; 2010 Oct; 102(5):503-8. PubMed ID: 20589706
[TBL] [Abstract][Full Text] [Related]
10. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
[TBL] [Abstract][Full Text] [Related]
11. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
14. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.
Reece-Smith AM; Saunders JH; Soomro IN; Bowman CR; Duffy JP; Kaye PV; Welch NT; Madhusudan S; Parsons SL
Ann R Coll Surg Engl; 2017 May; 99(5):378-384. PubMed ID: 28462649
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
[TBL] [Abstract][Full Text] [Related]
17. [Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy].
Moldvay J; Pápay J; Puskás R; Furák J; Losonczy G; Matolcsy A
Magy Onkol; 2011 Jun; 55(2):105-9. PubMed ID: 21655476
[TBL] [Abstract][Full Text] [Related]
18. Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.
Reim D; Novotny A; Friess H; Slotta-Huspenina J; Weichert W; Ott K; Dislich B; Lorenzen S; Becker K; Langer R
J Pathol Clin Res; 2020 Oct; 6(4):263-272. PubMed ID: 32401432
[TBL] [Abstract][Full Text] [Related]
19. Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.
Podmaniczky E; Fábián K; Pápay J; Puskás R; Gyulai M; Furák J; Tiszlavicz L; Losonczy G; Tímár J; Moldvay J
Pathol Oncol Res; 2015 Apr; 21(2):423-31. PubMed ID: 25194563
[TBL] [Abstract][Full Text] [Related]
20. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
